Top image

David Thomas: Molecular Screening and Therapeutics Program (MOST)

RESEARCH TYPE
T1,T2
PROGRAM
Sydney Catalyst Supported
TAGS
    Genetics/genomics
    Personalised medicine
    New therapies and diagnostics
STATUS
In Progress

The rapid advance in genomic technologies presents the unprecedented opportunity to molecularly phenotype cancers and link genetic information to therapeutic opportunities for individual patients. However, therapeutic translation of genomic opportunities has not paralleled the pace of scientific discovery, due to the decreased efficiency and increased costs of clinical research.

The fundamental premise of the Cancer Molecular Screening and Therapeutics (MoST) Program is that innovations in clinical trial design are needed to expedite translation of discovery into improved health outcomes. MoST has taken a novel design approach whereby a central framework protocol governs a molecular screening platform that links to multiple clinical substudies for new treatments and/or indications. The framework describes the overarching study methodology, process and organisation of the program and treatment-related information is appended to this protocol in substudy protocol addenda. The design streamlines the development and allows the rapid assessment of new personalised treatments via the individual signal-seeking substudy modules slave to the governing framework. The findings of the MoST program will form a precursor trial that will inform the more efficient and successful development of formal phase II testing of novel indications for therapy.

The MoST team consists of Garvan's Professor David Thomas (program chair) and Dr Dominique Hess (program manager for screening at Garvan) and from the CTC: John Simes (program co-chair), Wendy Hague (clinical trials director), Katrin Sjoquist and Chee Lee (clinical leads), Lucille Sebastian (program manager for trials at CTC) and Yvonne Cheung (clinical trial coordinator).

Media Release on the NHMRC CTC and Garvan Collaboration: Ground breaking trial brings personalised treatments to those with rare cancers, Garvan website 23 August 2017 

More about the study can be found on Garvan's website here

 

 

 

You might also be interested in...

  • T1
    Ashleigh Morgan: From mice to men: biomarker driven classification of pancreatic cancer to define novel targetable molecular subtypes
    Due to the extremely poor prognosis of pancreatic cancer, and current therapies only being marginally effective, there is an urgent need to develop novel therapeutic strategies. This study aims to...
      Biomarkers
      Personalised medicine
      New therapies and diagnostics
  • T1
    Ben Kong: Towards a therapeutic vaccination for glioblastoma multiforme
    The ultimate objective of Ben's research is to create an effective dendritic cell based vaccine for glioblastoma multiforme by exploiting knowledge of DC biology to find the optimum combination of...
      Dendritic cell
      Immunotherapy
  • T1
    CINSW RIGs and REGs
    The CINSW Research Equipment and Infrastructure Grants Program is directed to providing substantial funding for key research platforms, core equipment and capacities to enhance the cancer rese...
      Research Equipment
      Research Infrastructure
      CINSW
  • T1
    Claire Vennin: Preclinical targeting of the extracellular matrix to improve chemotherapy and reduce metastasis in patient-stratified models of pancreatic cancer using innovative imaging technologies
    A major challenge in cancer research is to understand and counteract mechanisms of drug resistance. This project will (1) shed light on the role of the ECM in chemoresistance and (2) guide the dev...
      Biomarkers
      New therapies and diagnostics
  • T1
    David Croucher: Mapping and manipulating therapeutically induced JNK network architecture to tackle breast cancer chemoresistance
    The current generation of cancer therapies mostly target components of signalling pathways, being either small molecule inhibitors or monoclonal antibodies to cell surface receptors. It is fas...
      Breast Cancer
      Chemo resistance
  • T1
    Fast Linear Laser Scanning Technology: The ZEISS LSM 800 Confocal Microscope for the Open Access, Bosch Institute Advanced Microscopy Facility
    Funding was awarded for revolutionary technology, the ZEISS LSM 800 confocal microscope with Airyscan, for the Open-Access, Multi-User Bosch Institute Advanced Microscopy Facility (AMF) at the Uni...
      CINSW Research Equipment Grant
  • T1
    Hayley Suen & team: Restoring the Function of Clonal Cytotoxic T cells in Multiple Myeloma to Develop Novel Therapies and Define the Antigenic Landscape
    Multiple myeloma is an incurable disease so new treatments are required to provide a cure for patients. An attractive form of treatment is the use of a patient's own T cells to fight their cancer....
      Immunotherapy
      New therapies and diagnostics
      Myeloma
  • T1
    Helen McGuire: Development of a novel test to predict clinical response to checkpoint therapy in lung cancer and mesothelioma
    Immune checkpoint inhibitor therapy has provided new hope to cancer patients whose tumours have resisted conventional therapy. One of the most recent success stories has been effective treatment o...
      Immunotherapy
      New therapies and diagnostics
      Lung cancer
      Mesothelioma
  • T1
    Jeff Holst & team: Targeting glutamine metabolism to starve triple-negative breast cancer
    Jeff's team are studying nutrient pumps that bring the amino acid glutamine into cancer cells. They have discovered that these pumps are increased in triple-negative breast cancer, a subset that h...
      Cancer metabolism
      New therapies and diagnostics
      Breast Cancer
  • T2
    John Simes: MDT scoping project
    The aim of this research was to describe the multi-disciplinary teams (MDTs) in our consortium and to share findings with survey participants to provide them an opportunity to learn more abou...
      MDT
  • T2
    Jolyn Hersch: Supporting informed choice for management of screen-detected Ductal Carcinoma in Situ (DCIS) among older women (70 years and over)
    Breast screening often finds ductal carcinoma in situ (DCIS) - cell changes which may or may not become cancer later on. Treatments for DCIS (surgery, radiation and drugs) have harmful side effect...
      Psychosocial
      Breast Cancer
  • T2
    Kate White & team: The financial impact of cancer treatment on Australian patients and families
    It is recognised that individuals and their families experience financial costs associated with the diagnosis of cancer and subsequent treatment.  Little attention has been paid to identifyin...
      Psychosocial
      Cancer costs
  • T1
    LC-PLAT - Lung Cancer Cohort - a Platform to Study Serial Biospecimens and Matched Clinical Data
    The project aimed to optimise a platform for the collection of serial lung cancer tissue and blood biospecimens for research during routine clinical practice. Prospective biobanking and collection...
      Lung cancer
      Biobanking
  • T1
    Lorraine Chantrill and team: IMPACT Trial
    Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) aimed to improve outcomes for patients with advanced pancreas cancer by using molecular analysis of tumor tissue to guide treatment sele...
      Personalised medicine
      Clinical Trials
      Pancreatic cancer
      Treatment
  • T1
    Magdalena Budzinska: Discovering Novel Non-Invasive Diagnostic and Prognostic Markers in Hepatocellular Carcinoma
    Magdalena's research addresses the urgent need in HCC management for markers that predict HCC propensity and behaviour. It has the potential to be translated into clinical practice at the level...
      Biomarkers
      New therapies and diagnostics
  • T1
    Mark Larance: Nutrient Deprivation and the Protective Proteome for the Prevention of Disease
    Cancer is a major cause of illness and death in Australia. Key risk factors for colorectal cancer and many other cancer types are poor diet, obesity and age. In animals, short periods of nutrient ...
      Cancer metabolism
      Colorectal cancer
      Proteomics
  • T2
    Nicole Rankin and Team: Sydney Catalyst Member Experience Survey
    The aim of this research was to qualitatively explore the experiences of members of Sydney Catalyst to identify members' understanding and perceptions of translational research, benefits of member...
      Member Experience
  • T1
    Philip Hogg: ACRF Centenary Cancer Research Centre
    The goal of the ACRF Centenary Cancer Research Centre is to understand the link between diet, metabolism and tumour initiation and development at a molecular level, and to design new therapies usi...
      Cancer metabolism
      New therapies and diagnostics
  • T1,T2
    Philip Hogg: Measure of thrombotic risk in cancer patients
    Thrombotic events are a major cause of death in cancer patients and are associated with worsened short‐term and long‐term survival. Prof Hogg and his team developed a new diagnostic test for ...
      Thrombosis
  • T1
    Roger Bourne & team: Gold-standard assessment of prostate cancer MRI accuracy
    A recent health economics analysis identified doctors' lack of confidence in prostate MRI as a major inhibitor to increased choice of active surveillance for low risk prostate cancer. Furthermore,...
      Imaging
      Urogenital
      Prostate
      MRI
  • T1
    Sarah Sutherland: Novel targets for a new generation of therapeutic cancer vaccines
    DC vaccines are well tolerated and can induce an anti- tumour immune response. Current vaccine strategies use in vitro generated "DC" which are loaded with antigen, stimulated and transfused back ...
      Dendritic cell
      Immunotherapy
      Urogenital
  • T1
    Sonia Yip: Biobanking - Patient and healthcare Professional Attitudes and Experiences of universal consent (B-PPAE)
    The Biobanking Qualitative Evaluation Project was initially developed to explore patient and health professional views of universal consent for biobanking procedures. It was later expanded to canv...
      Lung cancer
      Biobanking
      Consent
  • T1,T2,T3
    Sydney Catalyst Scholarships Awarded pre July 2016
    We aim to encourage training and development of outstanding researchers and clinicians from within Sydney Catalyst units, who have the potential to develop highly significant ca...
      Scholarships
  • T1,T2,T3
    Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)
    The program will develop infrastructure to support translational cancer research, initially with a focus on lung cancer. Specifically, EnRICH will assemble a prospective cohort of 1000 newly d...
      Epidemiology and health services research
      Implementation research
      Knowledge translation
      Lung cancer
  • T1
    The Next Wave of Cancer Genomics: Resolving Complex Structural Variants and Tumour Heterogeneity with Linked Short-Read
    Large genomic structural rearrangements are just important as short mutations in cancer pathogenesis. However, these critical events are often missed by conventional sequencing technologies. The f...
      CINSW Research Equipment Grant
  • T1
    Thomas Cox: Biomechanical priming of organotropism in metastasising breast cancer cells
    Breast cancer is the most common cancer in women worldwide. It is estimated that more than 1.7 million new cases of breast cancer occurred among women worldwide in 2012. We already know that tissu...
      Breast Cancer
      Tissue stiffness
      Metastasis